Zealand Pharma A/S

Zealand Pharma A/S

231.70
DKK
-8.10
(-3.38%)
44.09EPS
6.14P/E
18.05BMarket Cap
Feb 25Next Earn

Q3 FY2026 · Earnings Call TranscriptNovember 12, 2026

Operator

Good day and thank you for standing by. Welcome to the Zealand Pharma interim report Q3 2026 conference call.

At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.

To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised.

To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Eric Rojas. Please go ahead.

Eric Rojas

Thank you, Sandra. Thank you to everyone for joining us today to discuss Zealand Pharma's results for the first nine months of 2026.

The related company announcement is available on our website at zealandpharma.com. As outlined on the slide, I would like to remind listeners that during today's call, we will be making forward-looking statements that are subject to risks and uncertainties.

Turning to today's agenda, joining me on this call is Adam Steensberg, President and Chief Executive Officer; Utpal Singh, Chief Scientific Officer; David Kendall, Chief Medical Officer; and Henriette Wennicke, Chief Financial Officer. All speakers will be available for the Q&A session.

I will now hand the call over to Adam.

Adam Steensberg

Thank you, Eric, and welcome, everyone. One year ago, we set out our Metabolic Frontier 2030 strategy.

This quarter showed what it looks like in motion. With petrelintide, we reported positive ZUPREME-2 results, the first data to show its promise as a standalone treatment for those living with overweight or obesity and type 2 diabetes.

Together with Roche, we launched the global registrational Phase 3 program. That is a defining step towards establishing petrelintide as a future first-choice therapy for chronic weight management.

Our partner, Boehringer Ingelheim, reported SYNCHRONIZE-2 results and, most recently, SYNCHRONIZE-CVOT, which showed a favorable cardiovascular safety profile compared to placebo. With the registrational Phase 3 program now complete, BI is moving forward with a global regulatory submission in obesity in 2027 and is widening the program with new Phase 3 trials in type 2 diabetes and three Phase 3b trials, which David will cover.

In rare diseases, the positive CHMP opinion for Zydovia, glepaglutide, marks the first major advancement in short bowel syndrome treatment in Europe in more than a decade. In our early pipeline, our novel Kv1.3 ion channel blocker, ZP9830, delivered positive results and moved into Phase 1b in plaque psoriasis.

While we're advancing today's pipeline, we are also building what comes next. We opened our new research hub in Cambridge and entered a collaboration with Generate Biomedicines to develop AI-engineered protein therapeutics.

Utpal will take you through both shortly. A quarter with strong execution, and we are not slowing down.

Before I hand over, let me take a step back and frame where all this progress leaves us. We have four late-stage assets in our pipeline, all discovered in our labs here at Zealand.

Two are partnered or licensed and address obesity and metabolic health: petrelintide with Roche and survodutide with Boehringer Ingelheim. The other two are rare disease assets, dasiglucagon and glepaglutide, which we intend to license.

Milestones, royalties, and profit share from existing partnerships, together with more than $2 billion on our balance sheet, gives us a clear path to sustainable revenue and earnings growth from our current clinical assets without relying on dilutive funding. That strength gives us the freedom to build, and we will reinvest in the future.

Internally, we're building through our Cambridge research hub, expanding in Copenhagen, advancing our early programs, and scaling the organization. Externally, we are bolstering the pipeline through disciplined collaboration agreements.

That is how we deliver on Metabolic Frontier 2030. With that, I will turn over the call to our Chief Scientific Officer, Utpal.

Utpal Singh

Thank you, Adam. Great to be here today, and thank you all for joining us.

I want to open my comments with a simple comparison. At the end of 2025, at the Capital Markets Day, we were a peptide-based discovery and development company.

We had more than 25 years of metabolic health research and development experience supporting these efforts, and we'd delivered more than 10 clinical candidates into the clinic and had two Zealand assets which were brought to the market. Today, our pipeline spans peptides, small molecules, biologics, and conjugates.

In less than a year, we have become a multi-modality metabolic health company. I think that speaks volumes about the speed and agility with which we operate at Zealand Pharma.

We did that by combining our internal discovery engine with external innovation. Our partnership with OTR Therapeutics gives us access to small molecules.

Our collaboration with Generate Biomedicines brings AI-engineered protein therapeutics, including biologics and conjugates, and opens a new approach to polypharmacology. Together with our Copenhagen and Cambridge sites, that gives us access to capabilities and talent globally across Denmark, US, and China.

Cambridge deserves a few words of its own. With the opening of our research hub there, we have added a second research site that expands the platform beyond our core peptide expertise into hybrid modalities, including biologics and conjugates.

The platform is built around automation and advanced modeling, with one main purpose: to shorten the cycle time from idea to clinic. Cambridge is home to more than 600 life science companies.

We're actively hiring at the site, and we expect continued growth, and we've joined the Cambridge Chamber of Commerce. This is a long-term investment, bridging two leading life science communities.

We have more tools in our toolbox, and we're investing in external innovation as well as our internal engine. What comes next?

We expect to nominate the first wave of preclinical candidates from the strategy in the not-too-distant future, which leads us towards multiple Phase 1 starts each year. That is the path to industry-leading idea to cycle times and 10 clinical programs by 2030, as laid out in the Metabolic Frontier 2030.

With that, I will hand over to David Kendall to take through our clinical pipeline. David?

David Kendall

Thanks much, Utpal. I will begin today with an overview of the Zealand Pharma pipeline.

The third quarter was another busy period for our clinical teams, as Adam has just shared. Taken together, this is the late-stage and early-stage progress that underpins our path to five launches in 2030, and serves as a testament to the incredibly committed and talented teams we have at Zealand Pharma.

Let me start with petrelintide, which we believe can be an ideal first choice in chronic weight management: effective, exceedingly well tolerated, easy to start, and easy to stay on. As a reminder, in the Phase 2 ZUPREME-1 trial, petrelintide delivered up to 10.7% mean weight loss at week 42, and nearly all participants on petrelintide lost weight.

Discontinuations due to gastrointestinal adverse events were 1.5% on petrelintide compared to 0% on placebo. This quarter, we added the ZUPREME-2 results in 220 individuals with overweight or obesity and co-existing type 2 diabetes.

Petrelintide delivered up to 9.2% mean weight loss at week 28, a meaningful result at a significant earlier time point in a population where weight loss is typically more difficult to achieve. Hemoglobin A1c was reduced by up to 0.65 percentage points compared with an increase of 0.23% on placebo.

Discontinuations due to GI adverse events were comparable on petrelintide and placebo: only 1.9% on petrelintide and 1.7% on placebo. The safety and tolerability profile was consistent with what was observed in ZUPREME-1.

Taken together, these two Phase 2 trials support a tolerability profile that is generally comparable to placebo alongside double-digit weight loss, which is exactly the profile we believe the majority of people need when they choose to initiate treatment for weight management. It's also the profile that supports a treatment that allows individuals to stay on therapy for the long term.

Based on these data, we and Roche have initiated the Phase 3 program that consists of three registrational trials: ZUPREME-3 in people with overweight or obesity, ZUPREME-4 with overweight, obesity, and type 2 diabetes, and ZUPREME-5 in those with overweight or obesity and co-existing cardiovascular disease risk. The program is designed to confirm the efficacy and safety and first-choice potential of petrelintide and generate the robust longer-term evidence needed to support regulatory filings.

Beyond monotherapy, we and Roche expect to initiate the Phase 2 ZYNERGY trial in the fourth quarter this year. ZYNERGY will evaluate petrelintide in combination with linesepitide, Roche's GLP-1/GIP receptor dual agonist, in people with overweight or obesity, with or without type 2 diabetes.

As a reminder, profits for this combination therapy are also shared with Roche in both the US and Europe. Turning to survodutide, a novel glucagon/GLP-1 dual agonist, this week's SYNCHRONIZE-CVOT readout completes the registrational Phase 3 program in obesity for our partner, Boehringer Ingelheim.

With a broad body of evidence now in hand across weight reduction, glycemic control, liver fat, and cardiovascular safety, we are happy to confirm that Boehringer Ingelheim are now moving forward with global regulatory submissions for survodutide in obesity in 2027. Across the four Phase 3 trials, the picture is consistent.

Survodutide delivered substantial weight reduction of up to 16.6% in SYNCHRONIZE-1, together with targeted visceral and liver fat reductions with limited loss of muscle mass. In SYNCHRONIZE-2, survodutide demonstrated weight reductions of up to 13.1% in people with type 2 diabetes, a population in which weight loss is typically more challenging, together with meaningful improvements in glycemic control.

In SYNCHRONIZE-MASH, 6 out of 10 participants achieved liver fat normalization. That is a profile built for metabolic health, not only for the number on the scale.

SYNCHRONIZE-CVOT adds cardiovascular dimensions to this data set. It is the first and only global cardiovascular safety trial of a glucagon/GLP-1 dual agonist, and it enrolled more than 5,500 individuals at elevated cardiovascular risk.

The trial met its primary endpoint. Survodutide cardiovascular safety was confirmed, and treatment did not increase the risk of major adverse cardiovascular events compared with placebo, with a hazard ratio of 0.89.

As in earlier trials, discontinuations due to GI events were higher on survodutide, mostly during the dose escalation under a protocol with limited flexibility for slower dose escalation, which the newer Phase 3 and Phase 3b trials look to address. Boehringer Ingelheim is also deepening its investment in survodutide, building a program that spans the full cardiometabolic and liver disease spectrum.

In MASH, a serious and increasingly common liver disease, the Phase 3 LIVERGENT program is ongoing, with results from an interim analysis expected in 2027. LIVERGENT is enrolling approximately 1,800 participants with F2 to F3 fibrosis and will assess long-term efficacy and safety.

LIVERGENT-Cirrhosis, in approximately 1,590 participants with MASH and compensated cirrhosis, assesses liver-related clinical outcomes. BI has also initiated a Phase 3 trial in participants with type 2 diabetes, assessing glycemic control over 56 weeks, and plans for three Phase 3b trials assessing key unmet needs in people living with obesity in the setting of real-world care delivery: SYNCHRONIZE-START will assess initiation and switching from either semaglutide or tirzepatide; SYNCHRONIZE-HERA, in women who are peri- or postmenopausal, will study the impact on women's health; and ELEVATE-LIVER will evaluate the effects of survodutide on cardiac structure and function in individuals with overweight or obesity and co-existing MASLD.

Importantly, these newer programs, including the LIVERGENT studies, use a more flexible, patient-centered dose escalation strategy than that utilized in the SYNCHRONIZE program, to better reflect real-world use and support tolerability. All together, this reflects the breadth of opportunity for survodutide across cardiometabolic and the liver disease spectrum, a focus beyond efforts at brute force weight loss and towards improvements in overall metabolic health.

Moving to rare disease, we are pleased to have received a positive CHMP opinion for Zydovia, glepaglutide, for the treatment of short bowel syndrome. The positive opinion represents the first major advance in short bowel syndrome treatment in Europe in more than a decade.

We look forward to the final decision by the European Commission, which is expected soon. The efficacy profile and simplified administration of glepaglutide is compelling.

In the Phase 3 trial, 66% of participants achieved clinical response, defined as at least a 20% reduction in weekly parenteral support volume in those with short bowel and intestinal failure, compared to 39% on placebo. Importantly, 14% of those treated with Zydovia were weaned off parenteral support, achieving enteral autonomy, as compared to no patients achieving this critical endpoint when treated with placebo.

Glepaglutide is dosed twice weekly in a ready-to-administer autoinjector, which would make it the first and only ready-to-use GLP-2 if approved today. Today's alternative is daily dosing with a vial and syringe, requiring a complex multi-step reconstitution process.

The commercial opportunity for glepaglutide remains significant, and we are actively engaged in partnership discussions for global commercialization. The Phase 3 EASE-5 trial is ongoing to support a US NDA, with participant recruitment progressing well.

Finally, I would like to close with an update on ZP9830, our novel Kv1.3 ion channel blocker. Kv1.3 is a voltage-gated ion channel upregulated on disease-driving T effector memory cells.

ZP9830 selectively blocks the channel, suppressing those pathogenic T cells while sparing other T cell populations. This provides ZP9830 pipeline-in-a-product potential across more than 80 autoimmune diseases, which together affect approximately 8% of the US population.

We now have reported positive topline data from the multiple ascending dose part of the Phase 1a trial in healthy volunteers. Multiple doses were well tolerated, with no serious or severe adverse events and no dose-limiting safety findings.

The pharmacokinetics support continued development in trials of longer duration. This follows the positive single ascending dose results, which were also well tolerated, with pharmacokinetics as predicted and pharmacodynamics consistent with Kv1.3 target engagement.

We recently initiated the Phase 1b trial in people with plaque psoriasis, which will compare two dosing regimens with placebo over eight weeks, with treatment-emergent adverse events as the primary endpoint and efficacy endpoints also included. A Phase 2 trial in additional autoimmune disease is planned to follow.

We are progressing this asset at accelerated speed and look forward to sharing more updates with you in the future. This has been another outstanding and exciting quarter for our clinical organization, and I want to thank the teams at Zealand Pharma, Roche, and Boehringer for their efforts and congratulate them on the continued process.

With that, I will now turn the call over to Henriette Wennicke, who will review our financial results for the first nine months of the year. Henriette?

Henriette Wennicke

Thanks, David, and hello, everyone. Let me start with the income statement for the first nine months of 2026.

Revenue was 4.5 billion DKK, driven by the Roche collaboration. It consists of the recognition of the 3.7 billion DKK Phase 3 initiation development milestone and the 798 million DKK first anniversary milestone.

Operating expenses, excluding other operating items, were 1.9 billion DKK. R&D were 1.6 billion DKK, reflecting our investment in the petrelintide franchise, including the start of the Phase 3 program, expanded investment in our research programs, and advancements on our clinical assets.

Other operating items of 631 million DKK relates to the royalty agreement with Royalty Pharma for rusfertide. Net financial items were positive 343 million DKK, driven by interest income and exchange rates adjustments.

In the first nine months of 2026, we delivered a profit of 3.5 billion DKK. Turning to the balance sheet, this give us the strength to invest into future growth.

We ended September with a cash position of 13.5 billion DKK. Cash flow from operations was an outflow of 1.6 billion DKK, and we returned 1.2 billion DKK to shareholders through the share buyback programs, which have now been completed.

That was partly offset by 1.5 billion DKK of non-dilutive funding, the 798 million DKK from the first anniversary payment from Roche and the first installment of 324 million DKK from the rusfertide agreement. Looking ahead, the balance sheet gets another boost in the fourth quarter.

Due to the initiation of the Phase 3, we will receive the $575 million cash milestone from Roche, which is partly offset by a $175 million payment for the contribution of linesepitide to the petrelintide-linesepitide combination. That is net $400 million in cash, corresponding to approximately 2.6 billion DKK that we will receive in the fourth quarter.

We will deploy this capital in line with our strategic priorities on this slide, which I also mentioned at the last call. Prudent cost control remains a key focus, and our approach stays the same: disciplined and focused on building long-term value.

Moving to the outlook for 2026. Our guidance for collaboration revenue of 4.5 billion DKK is unchanged.

We have narrowed our guidance for operating expenses, excluding other operating items, to 2.7 to 3.0 billion DKK. This update reflect our prudent and disciplined cost control while we continue to invest behind our priorities.

With that, I will turn the call back to Adam for concluding remarks.

Adam Steensberg

Thank you, Henriette. To close, let me bring it all together and take us back to the bigger picture, to show how three pillars takes us from ambition to sustainable value creation.

The first is Metabolic Frontier 2030, our mid-term target: five launches, more than 10 clinical programs, and lead in our industry in the speed from idea to clinic. The second is what makes it achievable: building on our partnership with Roche and Boehringer Ingelheim and the near- to mid-term product launches, we expect to receive significant revenue through milestones, royalties, and, with Roche, profit share.

Our collaborations with Generate Biomedicines and OTR Therapeutics and the new Cambridge site extend our reach into new modalities, paving the way to build a leading metabolic health pipeline. That brings us to the third pillar: delivering on the 2030 targets powered by these partnerships is how we become a metabolic health champion, getting our medicines to millions, delivering sustainable revenue and earnings growth, and being the partner of choice in metabolic health.

With that, thank you for your attention. I will now turn over the call to the operator, and we'll be happy to address your questions.

Operator

Thank you. As a reminder, to ask a question, you will need to press *11 on your telephone and wait for your name to be announced.

To withdraw your question, please press *11 again. We will now take our first question from the line of Benjamin Jackson from Jefferies.

Please go ahead.

Benjamin Jackson

Hi, thanks for taking the question. I've got one large question in and around financials and then one perhaps slightly more interesting one.

Just on the financial side, Henriette, I guess in terms of the guidance coming down to the bottom half, how much of that is because you were able to drive efficiencies or cost prudence through the business or versus how much is because maybe some trials have started a little bit later than you initially thought during the year? Then building off of that, any early thoughts you can provide for us about what we need to think about for the cost build into next year in and around OpEx?

Then making that one single question quite long, now that the buybacks complete, have you got any desire to return more capital to shareholders? Then my second question that definitely is a second question, in terms of the broader pipeline and the opportunity thinking about petrelintide, is there any chance that we could see some form of data either from ZYNERGY or additional that's going on for petrelintide in 2027?

I'm not entirely sure if there's an early data cut potential in that Phase 2 that could help you accelerate the program further. Any thoughts on those would be fantastic.

Thank you, and sorry for all the questions.

Adam Steensberg

Thank you, Ben, and I'll just start with this second question and then hand over to Henriette. As both Roche and we are extremely excited to get the ZYNERGY study started this quarter, and we will of course make sure that it recruits as fast as possible with the ambition of moving the program forward as fast as possible.

It's too early to guide on when you can expect data, and we will do that together with Roche as we progress the program. I can reassure you that we are very committed to get this moving forward.

Henriette?

Henriette Wennicke

Yes. Thanks, and thanks for the question, Ben.

I think it's very clear when we initiate the year, we had quite a broad guidance out there, and as last year we decided to narrow it here after the third quarter. This is due to, as always, tight capital management and cost control.

When you then look into next year, I think also it's been laid out here in the call our clear ambitions. Of course, now we have initiated the Phase 3 for petrelintide.

We will also soon initiate the fixed-dose combination trials, and of course we have the Kv1.3 ongoing. Then, as Utpal also mentioned, we are continuing to expand our research efforts.

I think these are some of the building blocks when you look at the OpEx that goes into next year. Continued investments going in.

When you then have a question around a share buyback, you're right. We have just concluded that here earlier October.

It was an opportunity for us to hand back to shareholders after we got the go on the Phase 3 decision together with Roche for petrelintide moving into Phase 3. No commitments on additional share buybacks for you today, but I think, as always, we have an active capital management allocation and look at the opportunities we sit with at hand.

Benjamin Jackson

Awesome. Thank you so much, guys.

Operator

Thank you. We will now take the next question from the line of Mohit Bansal from Wells Fargo.

Please go ahead.

Mohit Bansal

Great. Thank you very much for taking my question.

I have a question regarding the strategy, how you and your partner Roche are thinking about developing in cracking either alone or combo. I think the most important feedback we received after looking at the eloralintide plus tirzepatide data was interesting because specialists wanted to be combined for more weight loss or some kind of optimal profile for the agent.

When you talk to primary care, they want more flexibility. They want these drugs to be separated so that they can decide what to do with these agents and what not.

Would love to understand how you are thinking about it. Is it co-formulation that is the strategy that you should take forward or something else?

How are you thinking about it? Thank you.

Adam Steensberg

Thank you for your question. I think we are sitting with two extremely attractive programs, which serves different needs.

Remember, if we just start by viewing the overall, you can say, obesity pandemic, it's the biggest healthcare challenge of our time. We are now five years into managing obesity with two two kind of medicines that are based on GLP-1-based therapies.

We need many more tools to really get around the obesity pandemic. There are many patients out there with different needs, and that's why I think a good place to look is in other chronic diseases like diabetes, like hypertension, like dyslipidemia, where there are at least 10 different categories and combination opportunities to achieve, you can say, the clinical benefit ultimately that the patient needs.

When it comes to petrelintide monotherapy, as David also highlighted in his prepared remarks, then we see this as a very clear opportunity for a first-choice therapy when patients embark on a weight loss journey. That's what we also see in other chronic therapy areas, that very often you go from medicines that has a profile that delivered a clinically relevant effect like double-digit weight loss and with a placebo-like tolerability, it's easy to start and easy to stay on.

For the combination therapy, it's really the opportunity to address the weight loss needs in those who needs the highest weight loss, and that's where the combination of petrelintide and linesepitide looks to become a product that can serve such needs. It's also highly interesting, as you mentioned in your question, to consider patient groups who have, you can say, more established comorbidities, where we know of all the benefits that have already been highlighted for the GLP-1 class.

To develop the combination product for those who have the highest weight loss needs and for those who lives with the most, you can say, established consequences of the obesity pandemic when it comes to other clinical conditions. It's two quite unique value propositions, and, ultimately, we need more solutions.

Here we are just sitting with two fantastic opportunities to serve two different patient journeys.

Mohit Bansal

Got it. Thank you.

Operator

Thank you. We will now take the next question from the line of Haakon Ammer from Danske Bank.

Please go ahead.

Haakon Ammer

Great, thank you for taking my questions. I have two, please.

First on the development spending, the petrelintide program is becoming quite substantial. We have three Phase 3a trials, the potential Phase 3b programs, and the upcoming Phase 2 combination studies with linesepitide, potentially followed by Phase 3.

Can you give us a ballpark for the total development spend still ahead across the franchise? Then on glepaglutide, following the positive regulatory opinion in Europe, how do you weigh a deal now against funding EASE-5 yourselves, and potentially securing better terms after a positive readout?

What make partnering at this stage more attractive than waiting? Thank you.

Adam Steensberg

Thanks for your question, Haakon. I'll take the last one and hand over to Henriette for the first one.

If we start with glepaglutide, we are of course extremely pleased with the positive CHMP decision and look forward to hear the outcome of the final decision here in the coming weeks, hopefully. On the partnering front, we are of course seeing quite significant interest, as you can imagine, now that the product has this positive opinion from the European regulators, and we also, as David mentioned, seeing strong progress in recruitment into the EASE-5 study which are conducted to support a US filing.

We will make sure that we choose the right partner at the right time at the right terms to make sure we reach as many patients as possible with this program. We have strong interest, as you can imagine, based on the positive CHMP opinion and are in discussions, and will update later.

Henriette?

Henriette Wennicke

Thanks, Adam, and thanks, Haakon, for the question. Of course, we cannot reveal what the total development costs are, but as I also mentioned, we are investing significantly behind petrelintide, both with the three Phase 3 trials well on its way, and of course the fixed-dose combination as well.

Of course, this was also what was reflected in the deal with Roche that was allowing us to invest significantly behind the molecule. As previously mentioned, of course we have the finances and the capital to do so, we are putting all behind it to build a leading franchise.

Haakon Ammer

Got it. Thank you.

Operator

Thank you. We will now take our next question from the line of Romy O'Connor from Kempen.

Please go ahead.

Romy O'Connor

Hi, thank you for taking our questions and thank you for the presentation. Two for me.

The first, are you able to remind us of the survodutide deal terms with BI and whether you can provide any color on the milestones to be expected heading into next year? Then maybe a follow-up on a previous question between ZYNERGY and the combination.

You mentioned that the combination might be an opportunity to address the needs for a higher weight loss and those that live with the consequences of obesity. I was just wondering if you can give us an indication of a ballpark weight loss that you are perhaps looking at in this trial.

Thank you.

Adam Steensberg

Thanks for the question. I'll start with the second one again and hand over to Henriette.

On ZYNERGY, we are truly excited, and so are Roche, around the potential of combining petrelintide with this very strong clinical profile. Then linesepitide, I think we have also seen in this year how strong that GLP-1/GIP molecule actually looks to be.

We are looking forward to progress the fixed-dose development of this combination to really deliver a product ultimately to the market that can deliver a weight loss for those who are in the need for the highest weight losses. We will not guide on a specific number.

I think, honestly, in the future will be much more complex than just looking at the exact number. It's a profile of the drug.

We just think when we're looking at the profile of linesepitide and the profile of petrelintide, we are looking at a combination that has a huge potential to address the needs for many patients, those who need the highest weight loss and those who lives with the most severe consequences of obesity. It's one which I can reassure you both parties puts a lot of efforts behind, as well as the monotherapy that we have just pushed into Phase 3.

Henriette?

Henriette Wennicke

Thanks, and thanks for that question as well. On survodutide, the deal terms we have is of course we have €315 million outstanding in regulatory and commercial milestones, and then we have high single digit to low double-digit royalties on the product worldwide.

A very, you can say, attractive deal that was initiated at preclinical stage.

Romy O'Connor

Got it. Thank you.

Operator

Thank you. We will now take our next question from the line of Rajan Sharma from Goldman Sachs.

Please go ahead.

Rajan Sharma

Hi, thanks for taking my questions. I had one on petrelintide to start.

Just comparing the data across the ZUPREME-1 and 2 trials, it suggests that the step-down in weight loss that's typically seen between patients with and without type 2 diabetes might be less pronounced with petri across those two trials versus what we would typically expect from a GLP-1. Could you maybe just talk around your observations there?

Do you think that is actually a real signal or is it maybe just a chance finding from the trials? If not, what could be the biologic rationale for that?

Then secondly, just on glepaglutide, can you maybe just give us an update on the discussions that you're having there with partners? Are you looking for a global licensor there?

If that is the case, is the lack of US Phase 3 data a gating factor or would you maybe consider a multi-region deal where, given that you've potentially got an approved product by the end of this year, you could look to license it specifically to a European partner? Thank you.

Adam Steensberg

Thanks, Rajan. I'll take the second question and then hand over to David to address the first question.

If we just revisit the discussions on a glepa partnership, our preferred scenario is a global partnership for the asset for several reasons. We see it as an attractive, you can say, opportunity for a global opportunity.

That could also be a situation where we ultimately choose for regional partnerships. On the timing of it, I think it's really important to, of course, again, revisit that we have now a positive opinion for CHMP.

We are seeing good progress in the Phase 3 program that supports a US filing, and for a US launch, it's actually nice to have a partner on board sometime before such a situation. We think it's an attractive situation we're in right now.

That's also the feedback we get in our partnership discussions, the opportunity and the magnitude of a glepa rollout. Remember, already today if we look at the market opportunity, the existing market opportunity, it's north of a billion US dollars, and we are very pleased with the clinical profile of glepaglutide.

We actually also believe it presents an opportunity to expand that market dynamic with the first introduction of a novel therapy into these patients who are in a deep need for more treatments. We see good progress and would probably prefer to go for a global partnership.

David?

David Kendall

Thank you, Adam and Rajan. Thanks for the question.

As we have, I believe, postulated all along, there is a clear step-down, as you suggest, in weight-reducing effects of incretin-based therapies, particularly GLP-1-based therapies, which, in part, is likely due to the fact that incretin-based therapies are potent adjuncts to insulin secretion in a population who already has elevated insulin levels, a degree of insulin resistance. As weight comes down, as insulin levels are augmented, remembering that insulin is a storage hormone, you actually drive glucose utilization, but you also drive fat deposition and turn off fat oxidation when insulin levels increase.

It's the counterbalancing effects potentially in GLP-1-based treatments in the diabetes population that drive that diminution in weight loss in the type 2 diabetes population. Similarly, you're taking all this excess glucose and driving it into cells either to burn as energy or storage.

Amylin therapies, and particularly petrelintide, are not insulin secretagogues, remembering that native amylin is secreted at the same time you release insulin. While it has glucose-lowering effects, those are primarily the consequence of glucagon suppression, some effects on substrate delivery in the gut.

While your comment about is this a chance finding versus a real observation, we'll obviously have to wait till confirmation in Phase 3 in the diabetes and non-diabetes populations, but it certainly for us is a hopeful sign that the postulate that amylin-based therapies may preserve much of the weight-reducing effects in those with either diabetes or early degrees of glucose intolerance, we're optimistic. I hope that addresses both the mechanism and what we will look to see in the Phase 3 program.

Rajan Sharma

Thank you.

Operator

Thank you. We will now take the next question from the line of Xiang Deng from UBS.

Please go ahead.

Xiang Deng

Thank you for taking my questions. Two, please.

The first one is on the overall ZUPREME Phase 3 programs. You have three Phase 3 trials ongoing.

Just wondering for ZUPREME-5, is that a safety study? Just wondering, do you need all of the three to read out before you can actually file for obesity, please, for petrelintide monotherapy?

That's the first question. The second one is just wondering, I wonder if I could maybe going back to one of the previous question on the combo strategy.

Just wondering, you commented you are after the highest weight loss. Just wondering, should we actually think about the type of weight loss like retatrutide?

Just wondering, in that case, how do you think about the liver benefit from the glucagon part? Thank you very much.

Adam Steensberg

Thank you for your questions. I will just take the first one here.

If you look into the ZUPREME Phase 3 program, then ZUPREME-3 and 4, which address weight loss in obese individuals with and without type 2 diabetes, and then ZUPREME-5, which is the CV safety study. ZUPREME-5 is designed to address the regulatory needs in a European context, where you need to deliver a certain amount of cardiovascular events to address the safety aspect of any new molecular entity.

ZUPREME-3 and 4 are designed to address the need to demonstrate, you can say, efficacy in a relevant population of obese population with and without type 2 diabetes. Number five is, you can say, a study that addresses specific EU needs, but of course will also contribute to regulatory interactions in other jurisdictions down the line.

On the combo product, I think it's really important, as we have probably stated many times, that we as a company truly believe we need to move away from the weight loss Olympics and start to think about the specific weight losses that an individual patient need, and also the way that patient should have the weight loss. David, his very nice explanation around some of the differences between an amylin and a GLP-1 speaks directly to why it's actually an extremely interesting combination for those who needs the highest weight loss, instead of just going all out on a specific mode of action, then starting to address the need to reduce calorie intake and other metabolic benefits from multiple angles.

That's how you normally address those who needs the highest clinical response. That's where amylin, and in particular petrelintide and linesepitide, when we look at the profile, speaks directly to a product that can deliver a metabolically attractive weight loss in those patients who needs the highest weight loss.

That also of course goes for a high weight loss, but again, it's not just down to that specific number, it's also how you deliver that high weight loss. That's where we believe the combination of petrelintide and linesepitide has a very attractive profile.

Xiang Deng

Thank you.

Adam Steensberg

Thank you.

Operator

Thank you. We will now take the next question from the line of Kirsty Ross Storr from BNP Paribas.

Please go ahead.

Kirsty Ross Storr

Hi, thanks for taking my questions. Maybe just building on the R&D commentary, are you able to indicate a little bit more specifically where the lower costs stem from?

Is that lower than expected costs from ongoing trials, including the petri program, or are the savings coming from lower spend in the early-stage development programs? Then secondly on MASH and survodutide's readout next year, looking at you're alone in having a MASH readout next year, also kind of the non-incretin mechanisms reading out.

Could you just elaborate and remind us on how you see survo's positioning and the value proposition versus other anti-fibrotic mechanisms in development, the FGF21s, the THR-betas, ahead of the readout next year? Thank you.

Adam Steensberg

Thanks for your questions. I'll start with the second one and then hand the first one back to Henriette.

I think as Boehringer was also very clear in their messaging here when they completed the SYNCHRONIZE program with the CVOT data coming out earlier this week, that Boehringer plan for a launch first in obesity, and then we expect to see the MASH data coming out next year so they could expand into MASH, and then after that expanding into type 2 diabetes. If you think about the comorbidities that surrounds obesity, or that when people have lived with obesity for a long time, then actually MASH is one of the key comorbidities with a huge unmet medical need.

It's 75% of all obese individuals, they have some degree of fatty liver disease. And 35% have fatty liver disease.

It's actually more prevalent than many of the comorbidities that we normally discuss as cardiovascular events, or diabetes, or kidney disease. If you try to put that into context, then the MASH data will not only for survodutide be a specific MASH kind of opportunity, it's also expanding the reasons to prescribe in obesity, coming back to the whole notion around see obesity, think liver, as Boehringer is very, very strong in their communication around a major reason we believe in the future to treat weight loss and help people losing weight is to treat the metabolic consequences.

There, MASH is just such an incredibly important component. What is also important when you then take the other angle, that is when you treat MASH, it's of course to some degree preventive medicines because you want to prevent continuous disease development.

There we just know it's a high incentive for patients to also lose weight. It's actually difficult to compare that to some of the other modalities that doesn't carry that patient incentive of losing weight.

I just think we're looking at a unique opportunity here to both expand the usability in obesity, but also hopefully expand the stay time in a MASH setting. I would then just conclude on highlighting this thing, because I think it has been, maybe not been taken up enough yet, when you think about the profile of survodutide, a product that really targets the weight loss to the intestinal, metabolically bad fat that sits in the liver and among the intestines, and at the same time tend to preserve muscle mass with only 10% muscle loss, that is really a strong product for weight loss in itself.

If you then add that MASH component on top of that, that really expand the reasons to prescribe and to take these molecules. Henriette?

Henriette Wennicke

Thanks, Adam, and thanks, Kirsty, for the question around our narrowing our guidance to the lower end of the previous guidance range. You can say, of course, we are still within the guidance range we had out there, and as you also said, we have now narrowed it slightly.

I cannot comment on exactly where we have found those, you can say, savings, but it just reflects a continued mindset of prudent cost control across the organization. I think the progress we have demonstrated throughout the first nine months show that we have full speed on both the research, but also the clinical activities across the portfolio.

Eric Rojas

Hi, Sandra. We'll take one more question, please.

Operator

Thank you. We will now take a final question from the line of Prakhar Agrawal from Cantor Fitzgerald.

Please go ahead.

Prakhar Agrawal

Hi, thank you so much for taking my questions. I had a few.

Maybe firstly on petrelintide, there was a lot of interest around the benefit of amylin drugs on bone health, even going back to ADA this year, especially given 60% to 70% of obesity users are female and average age is 50. Any plans to test the bone health impact for petri to characterize this benefit more robustly, like some of your competitors are starting to do now?

Secondly, what's the latest thinking on long-acting obesity drugs, and whether a long-acting amylin, like a monthly or even longer duration, could be of interest as we think about the early-stage pipeline? Last question on the Kv1.3 ion channel blocker that's in a Phase 1 trial in psoriasis.

Even if there's a signal in psoriasis, is the plan to look for partnership after Phase 1b, or do you plan to develop the asset further? Thank you so much.

Congrats on the quarter.

Adam Steensberg

Thanks for your questions. On the bone health and more, you can say, broadly speaking, metabolic positive opportunities around amylin and, more specifically, around petrelintide, we have a lot of discussions right now, and we look very much forward to updating at future calls the direction we're going to take petrelintide in.

It's clear that when it comes to general weight loss, losing bone mass is something that is of a concern if you lose weight, especially if you are a woman. It's an area, of course, of high interest with some of the early data that have been demonstrated for the amylin class.

Long-acting amylins, other you can say, opportunities within the amylin class is definitely something we look into, and maybe Utpal can address that a little bit more. I'll just conclude here before I hand over to you, Utpal, on the Kv1.3 opportunity.

Once we have the data from the study in plaque psoriasis, and at that time also hopefully having the other study ongoing, we will consider initial conversations around potential partnerships. We realize that with the more than 80 diseases that we could potentially pursue with this molecule, partnering somewhat earlier rather than later could be an interesting opportunity for Zealand to really broaden and also continue to elevate the speed with which we take this molecule forward.

Utpal, do you want to share or address a little bit more on our thinking around amylin and

Utpal Singh

Sure. Thank you, Adam, and thank you for the question.

Certainly, as we take a look at the space, it's clear that from a patient-centricity standpoint, there are going to be people who prefer different approaches for weight loss. Some may prefer oral, some will prefer weekly injectables, and some would prefer much longer-duration therapy with less frequent injections.

Certainly from a Zealand standpoint, we want to make sure that we provide options to all of those different preferences that people will have in the marketplace. Yes, that's certainly an area of importance for us.

Prakhar Agrawal

Thank you.

Operator

Thank you. There are no further questions at this time.

I would now like to turn the conference back to Adam Steensberg for closing remarks.

Adam Steensberg

Thank you all for attending and for your questions. We look forward to future announcements and updates and to connecting in the coming weeks and months.

Operator

This concludes today's conference call. Thank you for participating.

You may now disconnect.